Rubius Therapeutics Inc. (RUBY)
Rubius Therapeutics Statistics
Share Statistics
Rubius Therapeutics has 0 shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 0 |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 85.39M |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.07 and the forward PE ratio is null. Rubius Therapeutics's PEG ratio is 0.
| PE Ratio | -0.07 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 1.04 |
| P/FCF Ratio | -0.1 |
| PEG Ratio | 0 |
Enterprise Valuation
Rubius Therapeutics has an Enterprise Value (EV) of 2.04M.
| EV / Sales | 0 |
| EV / EBITDA | -0.02 |
| EV / EBIT | -0.01 |
| EV / FCF | -0.01 |
Financial Position
The company has a current ratio of 2.54, with a Debt / Equity ratio of 0.07.
| Current Ratio | 2.54 |
| Quick Ratio | 2.54 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | -46.19 |
Financial Efficiency
Return on Equity is -1525.76% and Return on Invested Capital is -1412.7%.
| Return on Equity | -1525.76% |
| Return on Assets | -1000.71% |
| Return on Invested Capital | -1412.7% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-38.48M |
| Employee Count | 6 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 51.2M |
| Effective Tax Rate | -28.5% |
Stock Price Statistics
The stock price has increased by 5.26% in the last 52 weeks. The beta is 2.21, so Rubius Therapeutics's price volatility has been higher than the market average.
| Beta | 2.21 |
| 52-Week Price Change | 5.26% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 87.52 |
| Average Volume (20 Days) | 99.53K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -178.45M |
| Net Income | -230.86M |
| EBITDA | -118.35M |
| EBIT | -175.8M |
| Earnings Per Share (EPS) | -2.56 |
Balance Sheet
The company has 14.87M in cash and 1.1M in debt, giving a net cash position of 13.77M.
| Cash & Cash Equivalents | 14.87M |
| Total Debt | 1.1M |
| Net Cash | 13.77M |
| Retained Earnings | -856.68M |
| Total Assets | 23.07M |
| Working Capital | 12.26M |
Cash Flow
In the last 12 months, operating cash flow was -150.14M and capital expenditures -5.3M, giving a free cash flow of -155.45M.
| Operating Cash Flow | -150.14M |
| Capital Expenditures | -5.3M |
| Free Cash Flow | -155.45M |
| FCF Per Share | -1.72 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RUBY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1460.84% |
| FCF Yield | -983.62% |
Analyst Forecast
Currently there are no analyst rating for RUBY.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -81.9 |
| Piotroski F-Score | 2 |